Therapeutic targeting of acute lung injury and acute respiratory distress syndrome.
Therapeutic targeting of acute lung injury and acute respiratory distress syndrome.
复制标题
急性肺损伤与急性呼吸窘迫综合征的治疗靶点研究
DOI：
10.1016/j.trsl.2015.04.015
复制
发表时间：
2016-01
期刊：
影响因子：
--
通讯作者：
Ward PA
中科院分区：
文献类型：
--
作者：
Standiford TJ;Ward PA
尽管被诊断为急性呼吸窘迫综合征(ARDS)的患者数量相对较多，但FDA没有批准对ARDS的治疗。在这份报告中，我们提供了临床前研究的概述，以及对患有ARDS的人类已完成和未来的临床试验的描述。关于急性肺损伤(ALI)的临床前研究已经表明补体和补体受体的作用，以及组蛋白的演变作用，但这些途径的细节还不够清楚。消炎干预并没有令人信服的效果。各种细胞生长因子正在考虑用于临床研究。阻断补体激活或其产物的干预措施正在考虑之中。干细胞疗法在临床前研究中显示了有效性，这些研究推动了对患有ARDS的人类的I/II期试验。
There is no FDA approved treatment for acute respiratory distress syndrome (ARDS), in spite of the relatively large number of patients with the diagnosis. In this report, we provide an overview of preclinical studies as well as a description of completed and future clinical trials in humans with ARDS. Preclinical studies dealing with acute lung injury (ALI) have suggested roles for complement and complement receptors, as well as the evolving role of histones, but details of these pathways are inadequately understood. Anti-inflammatory interventions have not been convincingly effective. Various cell growth factors are being considered for clinical study. Interventions to block complement activation or its products are under consideration. Stem cell therapies have shown efficacy in preclinical studies, which have motivated phase I/II trials in humans with ARDS.